![Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.[v1] | Preprints.org Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.[v1] | Preprints.org](https://www.preprints.org/img/dyn_abstract_figures/2021/07/997d10d870ce55b3615ae59f2efd8c1a/graphical.v1.png)
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.[v1] | Preprints.org
![The lung microenvironment: an important regulator of tumour growth and metastasis | Nature Reviews Cancer The lung microenvironment: an important regulator of tumour growth and metastasis | Nature Reviews Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41568-018-0081-9/MediaObjects/41568_2018_81_Fig1_HTML.png)
The lung microenvironment: an important regulator of tumour growth and metastasis | Nature Reviews Cancer
![Clinical trial co-led by UCL leads to new bowel cancer drug approval | UCL News - UCL – University College London Clinical trial co-led by UCL leads to new bowel cancer drug approval | UCL News - UCL – University College London](https://www.ucl.ac.uk/news/sites/news/files/styles/medium_image/public/pembrolizumab-image_wiki.jpg?itok=UCdIs0kK)
Clinical trial co-led by UCL leads to new bowel cancer drug approval | UCL News - UCL – University College London
![Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial - The Lancet Healthy Longevity Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial - The Lancet Healthy Longevity](https://www.thelancet.com/cms/attachment/7a7d5d3a-428b-4293-bccb-2be588c11397/gr1.gif)
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial - The Lancet Healthy Longevity
![Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma - Pharmaceutical Technology Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2017/09/main-1249.jpg)
Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma - Pharmaceutical Technology
![Genomic disparities between cancers in adolescent and young adults and in older adults | Nature Communications Genomic disparities between cancers in adolescent and young adults and in older adults | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-34959-2/MediaObjects/41467_2022_34959_Fig1_HTML.png)